



**FOR IMMEDIATE RELEASE**  
**NEWS RELEASE**  
TSX Venture: **AMF**

**AMORFIX LIFE SCIENCES ANNOUNCES WILLIAM LAMBERT JOINS BOARD**

TORONTO, ON, June 16, 2006 – Amorfix Life Sciences Ltd. announced today the appointment of William Lambert to the Board of Directors and the resignation of Dr. Donald Rix as Director.

William Lambert is a Special Partner with Birch Hill Equity Partners where he advises on sourcing, monitoring and creating value in its investee companies. Mr. Lambert previously held the position of Managing Director of TD Capital, the private equity arm of the Toronto-Dominion Bank. He has over 12 years experience in merchant banking and investing, and 10 years experience in consulting. Mr. Lambert received his undergraduate degree from Massachusetts Institute of Technology and his M.B.A. from York University. He serves on the boards of a number of private companies and one other public company, Marsulex Inc.

“Bill brings excellent capital markets experience and has a strong focus on value creation which will be of great benefit to Amorfix at its stage of development. He has agreed to Chair the Audit Committee and we are very fortunate to have him join us. Dr. Rix will continue to be a strong supporter of Amorfix but could not continue in his directorship role. We thank Donald for his sound guidance,” stated Graham Strachan, Chair of the Board of Directors.

**About Amorfix**

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). Amorfix was formed to commercialize epitope protection technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and preventative therapies for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO  
Amorfix Life Sciences Ltd.  
416-482-3812  
[info@amorfix.com](mailto:info@amorfix.com)

James Parsons, CFO  
Amorfix Life Sciences Ltd.  
416-482-3814

**The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.**